WASHINGTON -- House Republicans unveiled a budget proposal that includes an estimated $715 billion in cuts to Medicaid and ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

"Antihypertensive medication administration time did not affect the risks and benefits of blood pressure-lowering medication ...

Long-term human albumin therapy failed to significantly improve long-term survival outcomes in cirrhotic patients with acute ...

Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC ...

Means argues that the cause of most health conditions -- including cancer, Alzheimer's disease, obesity, erectile dysfunction ...

President Trump on Monday signed a sweeping executive order setting a 30-day deadline for drugmakers to lower the cost of ...

Early findings from the SPARTAN phase II trial, presented at the National Kidney Foundation (NKF) Spring Clinical Meeting, ...

Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab ...

Like many of the almost 100,000 medical students in the U.S., I enrolled in medical school having grown up infatuated with ...

Tacrolimus outshined another immunosuppressive drug at extending relapse-free survival in kids with frequently relapsing or ...